Compare · MEDP vs NOTV
MEDP vs NOTV
Side-by-side comparison of Medpace Holdings Inc. (MEDP) and Inotiv Inc. (NOTV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MEDP and NOTV operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $15.36B, about 5509.3x NOTV ($2.8M).
- Over the past year, MEDP is up 72.2% and NOTV is down 95.4% - MEDP leads by 167.7 points.
- NOTV has been more active in the news (8 items in the past 4 weeks vs 5 for MEDP).
- MEDP has more recent analyst coverage (25 ratings vs 9 for NOTV).
- Company
- Medpace Holdings Inc.
- Inotiv Inc.
- Price
- $537.63-0.04%
- $0.08-14.45%
- Market cap
- $15.36B
- $2.8M
- 1M return
- +16.40%
- -72.65%
- 1Y return
- +72.22%
- -95.43%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- News (4w)
- 5
- 8
- Recent ratings
- 25
- 9
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Inotiv Inc.
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Latest MEDP
- Medpace downgraded by Robert W. Baird with a new price target
- Medpace downgraded by Jefferies with a new price target
- Director Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.27% to 10,352 units (SEC Form 4)
- Director Kraft Robert O. converted options into 33 shares, increasing direct ownership by 4% to 955 units (SEC Form 4)
- Director Carley Brian T converted options into 36 shares, increasing direct ownership by 0.11% to 32,825 units (SEC Form 4)
- Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
- New insider Hansman Brad W. claimed ownership of 697 shares (SEC Form 3)
- SEC Form 8-K filed by Medpace Holdings Inc.
- General Counsel & Corp. Secy. Ewald Stephen P exercised 16,349 shares at a strike of $138.87 and sold $7,357,050 worth of shares (16,349 units at $450.00) (SEC Form 4)
- SEC Form 8-K filed by Medpace Holdings Inc.
Latest NOTV
- Inotiv Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Inotiv Announces Confirmation of Plan of Reorganization
- Chief Financial Officer Taylor Beth A. covered exercise/tax liability with 5,864 shares, decreasing direct ownership by 4% to 139,616 units (SEC Form 4) (for tax liability)
- Chief Strategy Officer Sagartz John E covered exercise/tax liability with 6,071 shares, decreasing direct ownership by 0.83% to 729,626 units (SEC Form 4) (tax withholding)
- Chief Commercial Officer Hardy Adrian covered exercise/tax liability with 5,371 shares, decreasing direct ownership by 9% to 53,049 units (SEC Form 4) to satisfy withholding tax
- VP-Finance & Corp. Controller Freeman Jeffrey Brennan covered exercise/tax liability with 5,855 shares, decreasing direct ownership by 14% to 36,623 units (SEC Form 4) (tax withholding)
- EVP, GC, Sec'y & CCO Castetter Andrea covered exercise/tax liability with 5,800 shares, decreasing direct ownership by 11% to 49,200 units (SEC Form 4) (for tax liability)
- Chief Operating Officer Beattie John Gregory covered exercise/tax liability with 5,769 shares, decreasing direct ownership by 3% to 180,992 units (SEC Form 4) (withholding obligation)
- Inotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Inotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits